This Article Free upon publication Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mosca, L. Articles by Zinberg, S. Search for Related Content PubMed PubMed Citation Articles by Mosca, L. Articles by Zinberg, S. Related Collections Primary prevention Secondary prevention

(Circulation. 1999;99:2480-2484.)
© 1999 American Heart Association, Inc.

AHA/ACC Scientific Statement: Consensus Panel Statement

Guide to Preventive Cardiology for Women

Lori Mosca, MD, PhD, Chair; Scott M. Grundy, MD, PhD; Debra Judelson, MD; Kathleen King, PhD, RN; Marian Limacher, MD; Suzanne Oparil, MD; Richard Pasternak, MD; Thomas A. Pearson, MD, PhD; Rita F. Redberg, MD; Sidney C. Smith, Jr, MD; Mary Winston, EdD, RD; Stanley Zinberg, MD

Endorsed by American Medical Women's Association American College of Nurse Practitioners American College of Obstetricians and Gynecologists and Canadian Cardiovascular Society

Key Words: AHA Scientific Statements • prevention • women • coronary disease

Coronary heart disease (CHD) is the single leading cause of death and a significant cause of morbidity among American women.¹ Risk factors for CHD in women are well documented.² Compelling data from epidemiological studies and randomized clinical trials show that CHD is largely preventable. Assessment and management of several risk factors for CHD are cost-effective.³ Despite these facts, there are alarming trends in the prevalence and management of risk factors in women.² Smoking rates are declining less for women than for men. The prevalence of obesity is increasing, and 25% of women report no regular sustained physical activity.⁴ Approximately 52% of women >45 years old have elevated blood pressure, and 40% of women >55 years old have elevated serum cholesterol.⁵ The purpose of this statement is to highlight risk factor management strategies that are appropriate for women with a broad range of CHD risk. A more detailed description, including the scientific basis for these recommendations, is available in the 1997 American Heart Association scientific statement "Cardiovascular Disease in Women."²

Recently, the Centers for Disease Control and Prevention National Ambulatory Medical Care Survey⁶ showed clinicians are missing opportunities to prevent CHD. In this study of 29 273 routine office visits, women were counseled less often than men about exercise, nutrition, and weight reduction. In the multicenter Heart and Estrogen/progestin Replacement Study (HERS),⁷ only 10% of women enrolled with documented CHD had baseline LDL-cholesterol levels below a National Cholesterol Education Program (NCEP) target of 100 mg/dL. A recent national survey showed that women were significantly less likely than men to enroll in cardiac rehabilitation after an acute myocardial infarction (MI) or bypass surgery.⁸ This finding is especially important because post-MI patients not enrolled in cardiac rehabilitation are less likely to receive aggressive risk factor management.

Recommendations for the primary and secondary prevention of CHD have been published.^{9 10} Although those recommendations apply to women, there are aspects of risk factor management that are unique to women. Pregnancy and the preconception period are optimal times to review a woman's risk factor status and health behaviors to reduce future cardiovascular disease. Pregnant women should be strongly encouraged to discontinue smoking and not to relapse in the postpartum period. Avoidance of excess weight gain during pregnancy may reduce the risk of developing CHD in the future. An emphasis on prevention of CHD in postmenopausal women is particularly important because the incidence of CHD rises with age. The use of estrogen replacement therapy (ERT) to prevent CHD, osteoporosis, and possibly dementia is a difficult health decision for postmenopausal women. The potential benefits of therapy must be weighed against the possible risks, including breast cancer, gallbladder disease, thromboembolic disease, and endometrial cancer, although the last is reduced by concomitant use of a progestin.

The recent findings from HERS¹¹ have challenged previous observational data regarding the role of hormones in preventing subsequent cardiovascular events. HERS was the first large-scale, randomized, clinical trial in older postmenopausal women with confirmed coronary disease to test the efficacy and safety of hormone replacement therapy on clinical cardiovascular outcome in postmenopausal women. The study population included 2763 women (mean age 66.7 years) with established CHD randomly assigned to 0.625 mg conjugated equine estrogens (CEE) plus 2.5 mg of medroxyprogesterone acetate (MPA) per day or placebo. Participants were monitored for an average of 4.1 years for the main end point of nonfatal MI or CHD death. At study completion, no significant differences existed between groups for any cardiovascular end points.

Surprisingly, after 1 year, HERS showed an increase in cardiovascular events in the treatment arm, but in years 4 and 5, fewer events occurred than in the placebo arm. It has been hypothesized that possible early adverse effects of estrogen in women with CHD may be due to a procoagulant effect that may later be offset by an antiatherogenic benefit. MPA may also have adverse cardiovascular effects and may mitigate some of the beneficial effects of estrogen.² Although these hypotheses deserve further investigation, the overall null result from HERS does not support initiation of CEE combined with MPA in older postmenopausal women with confirmed coronary disease. For women with CHD already on ERT for 1 year, it may be reasonable to continue therapy while awaiting the results of a HERS follow-up study and other ongoing trials of ERT with clinical end points. The results of the HERS trial apply to women with preexisting CHD and may not apply to women free of vascular disease. Furthermore, this study does not take into consideration the other potential benefits of this therapeutic protocol, which are beyond the scope of this statement.

Data are lacking for determining the long-term cardiovascular effects of testosterone administered with ERT. Alternatives to traditional hormone replacement therapy are available, including soy phytoestrogens and selective estrogen receptor modulators (SERMs); however, a recommendation regarding their use for prevention of CHD has not been made at this time because of a lack of sufficient data.

Several other aspects of risk factor management are of heightened importance for women. Diabetes is a powerful risk factor in women, increasing CHD risk 3-fold to 7-fold compared with a 2-fold to 3-fold increase in risk in men.¹² This difference may be due to a particularly deleterious effect of diabetes on lipids and blood pressure in women.^{2 12} Therefore, recommendations are provided for management of diabetes with an emphasis on controlling concomitant risk factors.¹³ Low levels of HDL cholesterol are predictive of CHD in women and appear to be a stronger risk factor for women >65 years old than for men >65.¹⁴ Women tend to have higher HDL-cholesterol levels than men, and triglyceride levels may be a significant risk factor in women, especially older women. The current NCEP guidelines are outlined in the Table with a notation to consider more aggressive targets for HDL cholesterol and triglycerides in women.¹⁵ The NCEP also recommends the use of ERT before cholesterol-lowering drugs to reduce LDL cholesterol in postmenopausal women. In this statement, the recommendation has been modified to consider statins a first-line therapy in postmenopausal women on the basis of recent data that suggest women may have at least as much benefit from LDL-cholesterol reduction with statins as men.¹⁶

View this table: [in this window] [in a new window]   Table 1. Guide to Risk Reduction for Women

View this table: [in this window] [in a new window]   Table 1B. Continued

View this table: [in this window] [in a new window]   Table 1C. Continued

Recommendations for aggressive risk factor management are based on the future probability of a cardiovascular event. This strategy allows high-risk patients who have not yet had an event to be considered for more intensive treatment.¹⁷ It also recognizes that CHD is not a categorical event but rather a continuum of a progressive disease process. As the availability and use of noninvasive tools to detect asymptomatic CHD increase, the line between primary and secondary prevention may become less distinct. Substantial data support aggressive risk factor management in the setting of secondary prevention. However, because first cardiovascular events are often fatal in women, careful consideration should be given to individual risk factor management before onset of clinical CHD in women. The current recommendations are developed from previous guidelines and consensus panel statements along with newer gender-specific data when available.^{2 9 10 13 15 18 19 20 21 22 23} The recommendations can serve as a guide to risk factor management but cannot replace clinical judgment. As new knowledge is acquired, revised strategies for the prevention of CHD in women should reflect new science.

Acknowledgments

In addition to the American College of Cardiology and the American Heart Association, the following organizations assisted in the development and review of this document: American Medical Women's Association, American College of Nurse Practitioners, and American College of Obstetricians and Gynecologists.

Footnotes

"A Guide to Preventive Cardiology for Women" was approved by the American College of Cardiology Board of Trustees on February 22, 1999, and by the American Heart Association Science Advisory and Coordinating Committee on September 7, 1998.

A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596. Ask for reprint No. 71-0160. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or

References

1. 1998 Heart and Stroke Facts: Statistical Update. Dallas, Tex: American Heart Association; 1998.
   
2. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association: writing group. Circulation. 1997;96:2468–2482.[Medline] [Order article via Infotrieve]
   
3. Goldman L, Garber A, Grover S, Hlatky M (Task Force 6). 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task Force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. 1996;27:1020–1030.[Medline] [Order article via Infotrieve]
   
4. US Dept of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
   
5. Health United States, 1998 With Socioeconomic Status and Health Chartbook. Hyattsville, Md: National Center for Health Statistics; 1998.
   
6. Missed opportunities in preventive counseling for cardiovascular disease: United States, 1995. MMWR Morb Mortal Wkly Rep. 1998;47:91–95.[Medline] [Order article via Infotrieve]
   
7. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/progestin Replacement Study (HERS): the HERS Research Group. JAMA. 1997;277:1281–1286.[Abstract]
   
8. Thomas RJ, Miller NH, Lamendola C, Berra K, Hedback B, Durstin JL, Haskell W. National survey on gender differences in cardiac rehabilitation programs: patient characteristics and enrollment patterns. J Cardiopulmonary Rehabil. 1996;16:402–412.[Medline] [Order article via Infotrieve]
   
9. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction. Circulation. 1997;95:2329–2331.[Medline] [Order article via Infotrieve]
   
10. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill M, Hlatky M, Houston-Miller N, Krauss R, LaRosa J, Ockene I, Oparil S, Pearson T, Rapaport E, Starke R, the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2–4.
    
11. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA.. 1998;280:605–613.[Abstract/Free Full Text]
    
12. Manson JE, Spelsberg A. Risk modification in the diabetic patient. In: Manson JE, Ridker PM, Gaziano JM, Hennekens CH, eds. Prevention of Myocardial Infarction. New York, NY: Oxford University Press; 1996:241–273.
    
13. The American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care. 1998;21(suppl 1):S23–S32.
    
14. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol. 1992;2:161–176.[Medline] [Order article via Infotrieve]
    
15. National Cholesterol Education Program Expert Panel. Second report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel). Circulation. 1994;89:1333–1445.[Medline] [Order article via Infotrieve]
    
16. Gotto AM Jr. Cholesterol management in theory and practice. Circulation. 1997;96:4424–4430.[Medline] [Order article via Infotrieve]
    
17. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE (Task Force 5). 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007–1019.[Medline] [Order article via Infotrieve]
    
18. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA. 1996;276:241–246.[Abstract]
    
19. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson TA, Prewitt TE, Stone NJ, Horn LV, Weinberg R. Dietary guidelines for healthy American adults: a statement for health professionals from the Nutrition Committee, American Heart Association. Circulation. 1996;94:1795–1800.[Medline] [Order article via Infotrieve]
    
20. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Winters WL Jr, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for exercise testing: executive summary: a report from the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 1997;96:345–354.[Medline] [Order article via Infotrieve]
    
21. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446.[Abstract]
    
22. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russel RO, Smith EE III, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1996;94:2341–2350.[Medline] [Order article via Infotrieve]
    
23. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Washington, DC: US Dept of Health and Human Services; 1998.
    

This article has been cited by other articles:

				S. J. Nicholls, K. Wolski, I. Sipahi, P. Schoenhagen, T. Crowe, S. R. Kapadia, S. L. Hazen, E. M. Tuzcu, and S. E. Nissen Rate of Progression of Coronary Atherosclerotic Plaque in Women J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1546 - 1551. [Abstract] [Full Text] [PDF]

				L. Mosca, C. L. Banka, E. J. Benjamin, K. Berra, C. Bushnell, R. J. Dolor, T. G. Ganiats, A. S. Gomes, H. L. Gornik, C. Gracia, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update Circulation, March 20, 2007; 115(11): 1481 - 1501. [Full Text] [PDF]

				D. Wang, S. Oparil, Y.-F. Chen, M. A. McCrory, G. A. Skibinski, W. Feng, and A. J. Szalai Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2094 - 2099. [Abstract] [Full Text] [PDF]

				J. H. Mieres, L. J. Shaw, A. Arai, M. J. Budoff, S. D. Flamm, W. G. Hundley, T. H. Marwick, L. Mosca, A. R. Patel, M. A. Quinones, et al. Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Coronary Artery Disease: Consensus Statement From the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association Circulation, February 8, 2005; 111(5): 682 - 696. [Abstract] [Full Text] [PDF]

				L. Mosca, N. B. Merz, R. S. Blumenthal, M. J. Cziraky, R. P. Fabunmi, C. Sarawate, K. E. Watson, V. J. Willey, and E. J. Stanek Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting Circulation, February 1, 2005; 111(4): 488 - 493. [Abstract] [Full Text] [PDF]

				E. Biagini, A. Elhendy, J. J. Bax, V. Rizzello, A. F.L. Schinkel, R. T. van Domburg, M. D. Kertai, B. J. Krenning, M. Bountioukos, C. Rapezzi, et al. Seven-year follow-up after dobutamine stress echocardiography: Impact of gender on prognosis J. Am. Coll. Cardiol., January 4, 2005; 45(1): 93 - 97. [Abstract] [Full Text] [PDF]

				M. Gross, M. Steffes, D. R. Jacobs Jr, X. Yu, L. Lewis, C. E. Lewis, and C. M. Loria Plasma F2-Isoprostanes and Coronary Artery Calcification: The CARDIA Study Clin. Chem., January 1, 2005; 51(1): 125 - 131. [Abstract] [Full Text] [PDF]

				Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]

				Expert Panel/Writing Group, L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, et al. Evidence-based guidelines for cardiovascular disease prevention in women J. Am. Coll. Cardiol., March 3, 2004; 43(5): 900 - 921. [Abstract] [Full Text] [PDF]

				L. Mosca and for the Expert Panel/WritingGroup Summary of the American Heart Association's Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 394 - 396. [Full Text]

				L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, D. R. Judelson, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): e29 - 50. [Full Text]

				L. Mosca, L. J. Appel, E. J. Benjamin, K. Berra, N. Chandra-Strobos, R. P. Fabunmi, D. Grady, C. K. Haan, S. N. Hayes, D. R. Judelson, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Circulation, February 10, 2004; 109(5): 672 - 693. [Full Text] [PDF]

				L. Mosca, A. Ferris, R. Fabunmi, and R. M. Robertson Tracking Women's Awareness of Heart Disease: An American Heart Association National Study Circulation, February 10, 2004; 109(5): 573 - 579. [Abstract] [Full Text] [PDF]

				M. Neves-e-Castro Menopause in crisis post-Women's Health Initiative? A view based on personal clinical experience Hum. Reprod., December 1, 2003; 18(12): 2512 - 2518. [Abstract] [Full Text] [PDF]

				S. Mora, R. F. Redberg, Y. Cui, M. K. Whiteman, J. A. Flaws, A. R. Sharrett, and R. S. Blumenthal Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women: A 20-Year Follow-up of the Lipid Research Clinics Prevalence Study JAMA, September 24, 2003; 290(12): 1600 - 1607. [Abstract] [Full Text] [PDF]

				A. Rundle, D. Tang, L. Mooney, S. Grumet, and F. Perera The Interaction between Alcohol Consumption and GSTM1 Genotype on Polycyclic Aromatic Hydrocarbon-DNA Adduct Levels in Breast Tissue Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 911 - 914. [Abstract] [Full Text] [PDF]

				S. Natarajan, Y. Liao, G. Cao, S. R. Lipsitz, and D. L. McGee Sex Differences in Risk for Coronary Heart Disease Mortality Associated With Diabetes and Established Coronary Heart Disease Arch Intern Med, July 28, 2003; 163(14): 1735 - 1740. [Abstract] [Full Text] [PDF]

				The Exercise Prescription for Older Women Journal Watch Women's Health, March 5, 2003; 2003(305): 2 - 2. [Full Text]

				K. D. Graves and P. M. Miller Behavioral Medicine in the Prevention and Treatment of Cardiovascular Disease Behav Modif, January 1, 2003; 27(1): 3 - 25. [Abstract] [PDF]

				T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, P. Greenland, S. M. Grundy, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation, July 16, 2002; 106(3): 388 - 391. [Full Text] [PDF]

				T-M Asikainen, S Miilunpalo, P Oja, M Rinne, M Pasanen, K Uusi-Rasi, and I Vuori Randomised, controlled walking trials in postmenopausal women: the minimum dose to improve aerobic fitness? Br. J. Sports Med., June 1, 2002; 36(3): 189 - 194. [Abstract] [Full Text] [PDF]

				S. Oliver-McNeil and N. T. Artinian Women's Perceptions of Personal Cardiovascular Risk and Their Risk-Reducing Behaviors Am. J. Crit. Care., May 1, 2002; 11(3): 221 - 227. [Abstract] [Full Text] [PDF]

				J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]

				A. H. FRIEDLANDER The physiology, medical management and oral implications of menopause J Am Dent Assoc, January 1, 2002; 133(1): 73 - 81. [Abstract] [Full Text] [PDF]

				T. Tolbert, J. A. Thompson, P. Bouchard, and S. Oparil Estrogen-Induced Vasoprotection Is Independent of Inducible Nitric Oxide Synthase Expression: Evidence From the Mouse Carotid Artery Ligation Model Circulation, November 27, 2001; 104(22): 2740 - 2745. [Abstract] [Full Text] [PDF]

				L. Mosca, P. Collins, D. M. Herrington, M. E. Mendelsohn, R. C. Pasternak, R. M. Robertson, K. Schenck-Gustafsson, S. C. Smith Jr, K. A. Taubert, and N. K. Wenger Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association Circulation, July 24, 2001; 104(4): 499 - 503. [Full Text] [PDF]

				J. E. Manson and K. A. Martin Postmenopausal Hormone-Replacement Therapy N. Engl. J. Med., July 5, 2001; 345(1): 34 - 40. [Full Text] [PDF]

				D. Grady and S. B. Hulley Postmenopausal hormones and heart disease J. Am. Coll. Cardiol., July 1, 2001; 38(1): 8 - 10. [Full Text] [PDF]

				R. M. Robertson Women and Cardiovascular Disease : The Risks of Misperception and the Need for Action Circulation, May 15, 2001; 103(19): 2318 - 2320. [Full Text] [PDF]

				V. Bittner Estrogens, lipids and cardiovascular disease: no easy answers J. Am. Coll. Cardiol., February 1, 2001; 37(2): 431 - 433. [Full Text] [PDF]

				I. J. Goldberg, L. Mosca, M. R. Piano, and E. A. Fisher Wine and Your Heart : A Science Advisory for Healthcare Professionals From the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association Stroke, February 1, 2001; 32(2): 591 - 594. [Full Text]

				I. J. Goldberg, L. Mosca, M. R. Piano, and E. A. Fisher Wine and Your Heart : A Science Advisory for Healthcare Professionals From the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association Circulation, January 23, 2001; 103(3): 472 - 475. [Full Text] [PDF]

				G. C. Fonarow, W. J. French, L. S. Parsons, H. Sun, and J. A. Malmgren Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction : Data From the National Registry of Myocardial Infarction 3 Circulation, January 2, 2001; 103(1): 38 - 44. [Abstract] [Full Text] [PDF]

				M. B. Olson, S. F. Kelsey, V. Bittner, S. E. Reis, N. Reichek, E. M. Handberg, C. N. Bairey Merz, and for the Women's Ischemia Syndrome Evaluation (WISE Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: A report from the NHLBI-sponsored WISE study J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1565 - 1571. [Abstract] [Full Text] [PDF]

				J. A. Blakely The Heart and Estrogen/Progestin Replacement Study Revisited: Hormone Replacement Therapy Produced Net Harm, Consistent With the Observational Data Arch Intern Med, October 23, 2000; 160(19): 2897 - 2900. [Abstract] [Full Text] [PDF]

				L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]

				B. L. Abramson, L. Mosca, S. M. Grundy, D. Judelson, K. King, M. Limacher, S. Oparil, R. Pasternak, T. A. Pearson, R. F. Redberg, et al. Hormone Replacement Therapy and Cardiac Prevention Response Circulation, June 13, 2000; 101(23): e223 - 224. [Full Text] [PDF]

				E Sbarouni, C Kroupis, Z.S Kyriakides, K Koniavitou, and D.T Kremastinos Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease Eur. Heart J., June 2, 2000; 21(12): 975 - 980. [Abstract] [PDF]

This Article Free upon publication Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mosca, L. Articles by Zinberg, S. Search for Related Content PubMed PubMed Citation Articles by Mosca, L. Articles by Zinberg, S. Related Collections Primary prevention Secondary prevention